TITLE

Investigation of granulomatous prostatitis incidence following intravesical BCG therapy

AUTHOR(S)
Balasar, Mehmet; Doğan, Metin; Kandemir, Abdulkadir; Taskapu, Hakan Hakki; Cicekci, Faruk; Toy, Hatice; Gurbuz, Recai
PUB. DATE
July 2014
SOURCE
International Journal of Clinical & Experimental Medicine;2014, Vol. 7 Issue 6, p1554
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
In the present manuscript, we studied the incidence of granulomatous prostatitis in the prostatectomy specimen of the patients who underwent transurethral resection of the prostate (TURP) after superficial bladder cancer treatment with intravesical Bacillus Calmette-Guerin (BCG) and were diagnosed with benign prostate hyperplasia (BPH). The clinical data and histopathological specimen records of 472 patients who underwent TUR-P due to BPH diagnosis, obtained over a period of 6 years in the urology department of Private Konya Hospital, Konya, Turkey, were studied retrospectively. The cases were divided into two groups as (Group I) who did not undergo any treatment and as (Group II) who underwent BCG treatment. The frequency and the clinical course of the cases with granulomatous prostatitis were studied histopathologically. There were in total 472 patients who underwent TUR-P. Out of the 459 patients who did not undergo BCG treatment (Group I), the histopathological specimen records of 262 (57%) was BPH, of 197 (43%) BPH + chronic prostatitis. Of the second group, 13 cases underwent intravesical BCG treatment before surgical intervention due to superficial bladder CA diagnosis. In this group 4 of the cases were diagnosed as (30%) BPH, 9 as (70%) chronic prostatitis + BPH. 6 out of the 9 chronic prostatitis cases were chronic prostatitis, 2 caseous granulomatous prostatitis, 1 non-caseous granulomatous prostatitis. Granulomatous prostatitis cases should require no specific therapy. Conclusion: In patients with obstruction complaints following intravesical BCG treatment, granulomatous prostatitis should also be considered and treatment plans should be made accordingly.
ACCESSION #
97120995

 

Related Articles

  • Intravesical Bacillus Calmette-Guérin Therapy for T1 Superficial Bladder Cancer. Demkow, Tomasz; Alter, Andrzej; Wiechno, Paweł // Urologia Internationalis;Jan2008, Vol. 80 Issue 1, p74 

    Introduction: The management of transitional bladder cancer, which invades the lamina propria (pT1) and has a marked propensity for recurrence and progression, is controversial. Without adjuvant treatment the recurrence rate can be up to 80% and progression up to 50%. We retrospectively analyzed...

  • The Management of T1G3 Bladder Cancer. Bogdanovic, Jovo; Marusic, Goran; Djozic, Jasenko; Sekulic, Vuk; Budakov, Pavle; Dejanovic, Nebojsa; Stojkov, Jovan // Urologia Internationalis;Nov2002, Vol. 69 Issue 4, p263 

    Introduction: The treatment of T1G3 bladder cancer is still a controversial issue. Nowadays, intravesical bacillus Calmette-Guérin (BCG) instillation is considered to be the treatment of choice for patients with high-grade superficial bladder tumour after transurethral resection of all...

  • In Vitro Generation of Bacillus Calmette-Guerin-Activated Killer Cells. Brandau, S.; Bohle, A.; Thanhauser, A.; Ernst, M.; Mattern, T.; Ulmer, A.J.; Flad, H.-D. // Clinical Infectious Diseases;9/1/2000 Supplement 4, Vol. 31, pS94 

    Describes the induction of bacillus Calmette-Guerin (BCG)-activated killer (BAK) cells, which effectively lyse bladder tumor cells. Study of the immunostimulatory effects of BCG; Monoclonal antibodies that abolished BCG-mediated cytotoxicity; Beneficial effect of BCG on maintenance of the...

  • Quarter-dose BCG improves risk-benefit ratio. Guttman, Cheryl // Urology Times;Dec99, Vol. 27 Issue 12, p18 

    Reports that quarter-dose Bacille Calmette-Guerin has a clear ablative effect on superficial bladder cancer and also appears to minimize the risk of local adverse events compared with full-dose treatment. Phase II study by the European Organization for Research and Treatment of...

  • Genetics may provide clues to BCG non-response. Overmyer, Mac // Urology Times;Jul2000, Vol. 28 Issue 7, p19 

    Reports on the study conducted by researchers from the Hotel-Dieu de Quebec which revealed resistance to BCG immunotherapy among patients with bladder cancer. Role of the human natural resistance-associated macrophage protein 1 in the dampening or elimination of immunologic response; Allotype...

  • Efficacy and Safety of Bacille Calmette-Guerin Immunotherapy in Superficial Bladder Cancer. Lamm, Donald L. // Clinical Infectious Diseases;9/1/2000 Supplement 4, Vol. 31, pS86 

    Discusses the use of immunotherapy with intravesical bacille Calmette-Guerin (BCG) vaccines as an effective alternative approach to chemotherapy in the management of superficial bladder cancer. Expected long-term reduction in tumor recurrence, tumor progression and cancer mortality; Decrease in...

  • Nephrogenic Adenoma of the Urinary Bladder: Our Experience and Review of the Literature. Porcaro, Antonio B.; D'Amico, Antonio; Ficarra, Vincenzo; Balzarro, Matteo; Righetti, Rita; Martignoni, Guido; Cavalleri, Stefano; Malossini, Gianni // Urologia Internationalis;Apr2001, Vol. 66 Issue 3, p152 

    Objective: To assess our experience in the treatment and clinical outcome of bladder nephrogenic adenoma (NA) updating and reviewing the literature concerning this issue. Patients and Methods: From September 1976 to June 1999, bladder NA was diagnosed in 8 patients: 6 men and 2 women with a 3:1...

  • Gender Does Not Affect BCG Therapy.  // Renal & Urology News;Aug2010, Vol. 9 Issue 8, p41 

    The article reports on the study conducted by Stephen A. Boorjian of Fox Chase Cancer Center in Philadelphia, Pennsylvania, stressing that intravesical bacilli Calmette-Guérin (BCG) therapy does not cure high-risk non-muscle-invasive bladder cancer in men and women.

  • Role of Animal Models in Understanding Intravesical Therapy with Bacille Calmette-Guerin. Ratliff, Timothy L. // Clinical Infectious Diseases;9/1/2000 Supplement 4, Vol. 31, pS106 

    Discusses the use of the orthotopic animal model in mechanistic studies of Mycobacterium bovis strain bacille Calmette-Guerin (BCG) therapy for bladder cancer. Animal model's mimicking of the clinical treatment of bladder cancer; Importance of selecting a model that is most analogous to the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics